About this document
PML Risk in Dimethyl Fumarate MS Treatment by RALUCA Lupu is a document available to read on EtoBox.
This review discusses the incidence and clinical characteristics of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis treated with dimethyl fumarate (DMF), noting an incidence rate of 0.02 per 1000 patients. Key risk factors for PML include persistent severe lymphopenia and older age, although cases have also been observed in younger patients with normal lymphocyte counts. The review highlights the need for further understanding of DMF
- Author
- RALUCA Lupu
- Language
- EN